← Back to Home

Targeting Cancer Cells Through Dual Recognition: AbbVie Pays $40 Million to Partner with DISCO

This solid tumor collaboration focuses on bispecific therapies that recognize paired surface proteins simultaneously. Potential subsequent payments total up to $2.5 billion, but the research remains at the drug discovery stage, with no clinical evidence yet that it can reduce damage to normal tissue.

By SURL BioNews

Making cancer drugs more precise often requires more than finding markers on cancer cells; it also means identifying which markers are present in healthy tissue. AbbVie and Germany’s DISCO Pharmaceuticals announced a collaboration on November 19 to explore bispecific therapies that recognize solid tumors through paired cell surface proteins, seeking to add another condition for drug selectivity.

Under the terms disclosed by DISCO, the company will receive a $40 million upfront payment and is eligible for up to $2.5 billion in option, development and other milestone payments, as well as tiered royalties on global net sales. Subsequent payments depend on contractual conditions being met and cannot be treated as research and development funding already secured.

At the heart of the collaboration is an “AND logic gate” design: recognition shifts from a single marker to a combination of two proteins. DISCO hopes to identify protein pairs with greater tumor selectivity, making it easier for therapies to distinguish cancer cells from healthy cells. This is a design strategy intended to improve selectivity; its actual effects still require validation in subsequent research.

To find these pairs, the companies will combine DISCO’s DISCOtech cell surface protein mapping platform and AND logic gate drug discovery approach with AbbVie’s oncology research and development capabilities. The key to this research approach is identifying which combinations of surface proteins are suitable as drug recognition criteria, then designing candidate therapies accordingly.

The division of research and development responsibilities also leaves room for decisions in stages. According to Reuters, citing DISCO CEO Mark Manfredi, DISCO will be responsible for research and drug discovery. After specified research work is completed, AbbVie may choose to obtain exclusive licenses to some programs and take over subsequent development. The deal thus provides a route to future drug candidates, but whether individual programs are licensed remains subject to research results and subsequent decisions.

The information currently available to the public is insufficient to determine which cancers this strategy will address first. Reports from Reuters and BioPharm International indicate that the companies have not disclosed specific targets, tumor types or the number of programs covered, nor have they announced a timeline for entering clinical development. The announcement also provided no clinical data demonstrating an improvement in the safety margin between efficacy and toxicity.

The collaboration gives the concept of paired protein recognition the backing of a major pharmaceutical company’s resources. The next challenge is to translate selectivity into drugs suitable for development. Only if candidate therapies can reduce damage to normal tissue while retaining antitumor activity might the dual-recognition design translate into tangible treatment benefits for patients.

References

  1. DISCO Pharmaceuticals
  2. Reuters via Euronext
  3. BioPharm International